The objective is to assess the effect of Prosdex on six specific outcomes: (i) knowledge of PSA and prostate cancer-related issues – the principal outcome of the study; (ii) attitudes to testing; (iii) decision conflict; (iv) anxiety; (v) intention to undergo PSA testing; (vi) uptake of PSA testing.
††P-values for comparison of false negatives between intention vs no intention, and for comparison of false positives between intention vs no intention.
Figure 5 shows level of engagement in health-protective behaviors, stratified by intention vs action.
The models included adjustment for previously demonstrated associations of rural background and generalist vs specialist career intention on ultimate intended practice destination.
As would be expected, these analyses gave larger estimates (11.5 v 8.5 for intention to treat), but they are more prone to bias.
This poster compares the pathways experienced by two groups of patients with Brain Injuries (Traumatic vs Hypoxic) with the intention of influencing future planning strategies.
CRBSI occurred at a rate of 0.85 vs. 0.28 per 1000 catheter days in the heparin vs ethanol group by intention to treat analysis (incident rate ratio (IRR) for ethanol vs. heparin 0.17; 95%CI 0.02-1.63; p=0.12).
The overall consistency of results demonstrates that the findings are robust to variations in attrition (complete case v available case analyses), protocol fidelity (intention to treat v per protocol analyses), and choice of outcome measure.
Two-way ANOVA results revealed the relative advantage of concrete message on attitude toward the company and purchase intention among Koreans (vs. Americans) with high (vs. low) uncertainty avoidance.
For the two binary mixtures (Mixtures IV and V), composed with the intention of realising the principles of dissimilar action, IA did prove to be a reasonable approach for approximating the experimentally observed effects.
75, 76 Maintenance with erlotinib significantly increased OS vs placebo in the intention-to-treat advanced NSCLC patients (HR 0.81, 95% CI 0.70 to 0.95; P = 0.0088), but as observed for PFS, the absolute differences in OS with erlotinib were minor (12.3 vs 11.1 months).
